A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus

• Status: Not yet recruiting
• Trial end date: 2024-02-28
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to evaluate the response of glucagon to insulin-induced low blood sugar after administration of the study drug LY3532226 in participants with type 1 diabetes mellitus (T1DM). The study will also evaluate if LY3532226 helped participants to recover from insulin-induced low blood sugar condition compared to placebo. The study will last approximately 16 weeks excluding screening period.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Participants with type 1 diabetes mellitus (T1DM) for at least 2 years treated with insulin

• Body mass index (BMI) of 18.5 to 40.0 kilograms per meter squared (kg/m²)

• Are males or females not of childbearing potential

Exclusion Criteria:

• Have acute proliferative retinopathy requiring active treatment within 3 months of screening

• Have been treated with dipeptidyl peptidase-Ni, GLP-1 receptor agonists, GIP agonists, metformin or sodium-glucose cotransporter 2 inhibitors within the previous 3 months

• Have received systemic or inhaled glucocorticoid therapy

• Women of childbearing potential

• Are currently taking part in another clinical study trial involving medical research, or have participated within the last 30 days of screening in a clinical study involving a study intervention